Rottenstein Law Group Suggesting Medical Consultation Despite Recent Suggestion That Benefits of Fosamax Outweigh Risks
(New York, NY, May 16, 2011) The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, acknowledges a recent article which appeared in a well-known publication concluding that Fosamax is still a beneficial osteoporosis treatment. The article does advise users of the drug to consult with their physicians to make sure continued use will not increase the risk of side effects.
Earlier this month, the New England Journal of Medicine published a study showing a connection between Fosamax and other popular osteoporosis drugs (known as bisphosphonates) with an increased risk of a rare type of bone fracture that affects the femur.
12,777 women, aged 55 and older participated in the study, and 1,271 suffered from osteoporosis fractures, according to the New England Journal of Medicine article. Of these, 59 had the rare type of femur fracture. Approximately 78 percent of the women who participated in the study had taken one of the bisphosphonate drugs. The study linked osteoporosis drugs and fractures, yet researchers determined that the risk was “limited” and did not outweigh the benefits of taking the drug.
“These population-based nationwide analyses may be reassuring for patients who receive bisphosphonates,” according to lead researcher Dr. Per Aspenberg. “Although there was a high prevalence of current bisphosphonate use among patients with atypical fractures, the absolute risk was small.” Dr. Aspenberg also noted that for every one of these rare fractures caused by bisphosphonates, the drug protected 50 to 60 patients from more typical osteoporosis fractures.
Fosamax, despite being the most popular osteoporosis treatment on the market, has been linked to several serious side effects. In 2004, a casual connection was found between Fosamax and osteonecrosis of the jaw, a condition where the jawbone deteriorates due to a lack of blood flow. Recently, people have been suffering low impact femur fractures while in a sitting or standing position. Evidence is beginning to build showing that use of Fosomax or similar medications for the treatment of osteoporosis causes a dramatic increase in this kind of rare fracture to femur. Some physicians are now advising patients to take a break from Fosomax or other bisphosphonate drugs after as few as five, or as many as ten years of treatment.
The Rottenstein Law Group advises anyone with a friend or family member who has been prescribed Fosamax or another osteoporosis drug to recommend to that person that he or she consult a physician immediately, then speak to a qualified personal injury lawyer. The Rottenstein Law Group lawyers have a total of more than 25 years of experience fighting for the rights of clients who have suffered harm due to the negligence of powerful corporations. Affected individuals are advised to keep apprised of the latest news concerning the Fosamax femur fracture lawsuits by checking the Fosamax Femur Fracture Lawsuit Information Center for updated information. The site is equipped with easy-to-use social media features which will enable users to spread the word about the dangers of Fosamax.
About the Rottenstein Law Group
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, a lawyer with over two decades of experience in compassionate representation of clients in consumer product injury, mass tort, and class action law suits. For more information, please visit their Web site, or call (888) 9-ROT-LAW.
- Contact Information
- Nava Brahe
- PR Manager
- The Rottenstein Law Group
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.